Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort

(2019) Wanlong Wu et al.   ANNALS OF THE RHEUMATIC DISEASES

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis – Results of a Phase 2 Investigator‐Initiated, Multicenter, Double‐Blind Randomized Placebo‐Controlled Trial

(2019) Dinesh Khanna et al.   Arthritis & Rheumatology

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

(2019) Steven D Nathan et al.   Lancet Respiratory Medicine

Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators

(2018) Alexandru-Emil Matei et al.   ANNALS OF THE RHEUMATIC DISEASES

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study

(2018) Ariane L Herrick et al.   ANNALS OF THE RHEUMATIC DISEASES

Riociguat for the Treatment of Raynaud’s Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT)

(2018) Michael Huntgeburth et al.   CLINICAL DRUG INVESTIGATION

Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

(2017) Mônica Simon Prado et al.   Expert Opinion on Drug Metabolism & Toxicology

Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study

(2017) Vivien M. Hsu et al.   JOURNAL OF RHEUMATOLOGY

Systemic sclerosis

(2017) Christopher P Denton et al.   LANCET

Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence

(2017) Peter Sandner et al.   RESPIRATORY MEDICINE

RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis

(2017) Oliver Distler et al.   RESPIRATORY MEDICINE

Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II

(2017) Elizabeth R. Volkmann et al.   Arthritis & Rheumatology

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis

(2016) Rucsandra Dobrota et al.   ANNALS OF THE RHEUMATIC DISEASES

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

(2016) Dinesh Khanna et al.   Arthritis & Rheumatology

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study

(2016) Veronika K. Jaeger et al.   PLoS One

Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies

(2015) Clara Dees et al.   ANNALS OF THE RHEUMATIC DISEASES

Advances in cohort enrichment shape future of trial design

(2015) Yannick Allanore et al.   Nature Reviews Rheumatology

Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling

(2014) Christian Beyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

(2014) Britta Maurer et al.   ANNALS OF THE RHEUMATIC DISEASES

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

(2013) Frank van den Hoogen et al.   ANNALS OF THE RHEUMATIC DISEASES

Riociguat for the Treatment of Pulmonary Arterial Hypertension

(2013) Hossein-Ardeschir Ghofrani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis

(2012) Christian Beyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials

(2009) Sogol Amjadi et al.   ARTHRITIS AND RHEUMATISM

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial

(2009) Dinesh Khanna et al.   ARTHRITIS AND RHEUMATISM

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease

(2008) Arnold E. Postlethwaite et al.   ARTHRITIS AND RHEUMATISM